Seven-Year Experience From the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials.
Cudkowicz, M; Chase, MK; Coffey, CS; Ecklund, DJ; Thornell, BJ; Lungu, C; Mahoney, K; Gutmann, L; Shefner, JM; Staley, KJ; et al.
JAMA Neurology.
2020;
77:755-763.
Identifying epilepsy psychiatric comorbidities with machine learning.
Glauser, T; Santel, D; DelBello, M; Faist, R; Toon, T; Clark, P; McCourt, R; Wissel, B; Pestian, J.
Acta Neurologica Scandinavica.
2020;
141:388-396.
Association of Time to Treatment With Short-term Outcomes for Pediatric Patients With Refractory Convulsive Status Epilepticus.
Gainza-Lein, M; Fernandez, IS; Jackson, M; Abend, NS; Arya, R; Brenton, JN; Carpenter, JL; Chapman, KE; Gaillard, WD; Glauser, TA; et al.
JAMA Neurology.
2018;
75:410-418.
Pretreatment behavior and subsequent medication effects in childhood absence epilepsy.
Shinnar, RC; Shinnar, S; Cnaan, A; Clark, P; Dlugos, D; Hirtz, DG; Hu, F; Liu, C; Masur, D; Weiss, EF; et al.
Neurology.
2017;
89:1698-1706.
Pretreatment seizure semiology in childhood absence epilepsy.
Kessler, SK; Shinnar, S; Cnaan, A; Dlugos, D; Conry, J; Hirtz, DG; Hu, F; Liu, C; Mizrahi, EM; Moshe, SL; et al.
Neurology.
2017;
89:673-679.
Pharmacogenetics of antiepileptic drug efficacy in childhood absence epilepsy.
Glauser, TA; Holland, K; O'Brien, VP; Keddache, M; Martin, LJ; Clark, PO; Cnaan, A; Dlugos, D; Hirtz, DG; Shinnar, S; et al.
Annals of Neurology.
2017;
81:444-453.
Second monotherapy in childhood absence epilepsy.
Cnaan, A; Shinnar, S; Arya, R; Adamson, PC; Clark, PO; Dlugos, D; Hirtz, DG; Masur, D; Glauser, TA; Study, CA E.
Neurology.
2017;
88:182-190.
Rufinamide in patients with Lennox-Gastaut syndrome.
Clark, PO; Gibson, PA.
Nursing : Research and Reviews.
2016;
Volume 6:51-59.